Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q2 2022 U.S. Biopharma Recap

An increase in M&A and financing activity to end biopharma's Q2 have rekindled hope that we’re finally out of the biotech winter, while others fear it’s just a false spring. As companies continue to weather the storm, the focus remains on cash runway, quality news flow/clinical data, and consolidation. William Blair's Biopharma team shares perspectives in The Quarterly Rx: Q2 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Inflexion Raises a Multi-Asset Continuation Fund for Four Assets

    William Blair acted as a financial advisor to Inflexion Buyout V Investments LP, in connection with the successful close of a £2.3 billion multi-asset continuation fund, the Inflexion Continuation Fund I.

    Read more
  • College Was Awesome. Now What?

    College graduation marks the start of a career with new responsibilities and decisions. It can be an exciting time but filled with uncertainty.

    Read more
  • SevenRooms Has Agreed to be Acquired by DoorDash

    William Blair acted as the exclusive financial advisor to SevenRooms in connection with its pending sale to DoorDash (NASDAQ: DASH).

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures